Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".
Publication
, Journal Article
Piccini, JP; Stevens, SR; Chang, Y; Singer, DE; Lokhnygina, Y; Go, AS; Patel, MR; Mahaffey, KW; Halperin, JL; Breithardt, G; Hankey, GJ ...
Published in: Circulation
September 10, 2013
Duke Scholars
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
September 10, 2013
Volume
128
Issue
11
Start / End Page
e172 / e173
Location
United States
Related Subject Headings
- Vitamin K
- Thiophenes
- Stroke
- Morpholines
- Male
- Humans
- Female
- Factor Xa
- Embolism
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Piccini, J. P., Stevens, S. R., Chang, Y., Singer, D. E., Lokhnygina, Y., Go, A. S., … ROCKET AF Steering Committee and Investigators, . (2013). Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation, 128(11), e172–e173. https://doi.org/10.1161/CIRCULATIONAHA.113.004013
Piccini, Jonathan P., Susanna R. Stevens, Yuchiao Chang, Daniel E. Singer, Yuliya Lokhnygina, Alan S. Go, Manesh R. Patel, et al. “Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".” Circulation 128, no. 11 (September 10, 2013): e172–73. https://doi.org/10.1161/CIRCULATIONAHA.113.004013.
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10;128(11):e172–3.
Piccini, Jonathan P., et al. “Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts".” Circulation, vol. 128, no. 11, Sept. 2013, pp. e172–73. Pubmed, doi:10.1161/CIRCULATIONAHA.113.004013.
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, Patel MR, Mahaffey KW, Halperin JL, Breithardt G, Hankey GJ, Hacke W, Becker RC, Nessel CC, Fox KAA, Califf RM, ROCKET AF Steering Committee and Investigators. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10;128(11):e172–e173.
Published In
Circulation
DOI
EISSN
1524-4539
Publication Date
September 10, 2013
Volume
128
Issue
11
Start / End Page
e172 / e173
Location
United States
Related Subject Headings
- Vitamin K
- Thiophenes
- Stroke
- Morpholines
- Male
- Humans
- Female
- Factor Xa
- Embolism
- Cardiovascular System & Hematology